Arvinas Stock Forecast, Price & News

Arvinas (NASDAQ:ARVN) Frequently Asked Questions

Is Arvinas a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

How has Arvinas' stock been impacted by COVID-19 (Coronavirus)?

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARVN shares have increased by 71.6% and is now trading at $75.61.
View which stocks have been most impacted by COVID-19.

Are investors shorting Arvinas?

Arvinas saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 1,550,000 shares, a drop of 33.2% from the October 31st total of 2,320,000 shares. Based on an average trading volume of 329,700 shares, the days-to-cover ratio is currently 4.7 days. Approximately 3.6% of the company's stock are sold short.
View Arvinas' Short Interest.

When is Arvinas' next earnings date?

Arvinas is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Arvinas.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) announced its earnings results on Wednesday, November, 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of $2.13 by $3.07. The firm had revenue of $9.28 million for the quarter, compared to analyst estimates of $26.89 million. Arvinas had a negative trailing twelve-month return on equity of 27.02% and a negative net margin of 794.97%. The business's revenue was up 22.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.79) earnings per share.
View Arvinas' earnings history.

What price target have analysts set for ARVN?

16 brokerages have issued 12-month price targets for Arvinas' stock. Their forecasts range from $93.00 to $170.00. On average, they expect Arvinas' stock price to reach $128.44 in the next year. This suggests a possible upside of 69.9% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Who are Arvinas' key executives?

Arvinas' management team includes the following people:

• John G. Houston, President, Chief Executive Officer & Director (LinkedIn Profile)
• Sean A. Cassidy, Chief Financial Officer (LinkedIn Profile)
• Ian Taylor, Chief Scientific Officer
• Ronald Peck, Chief Medical Officer (LinkedIn Profile)
• Kimberly Wehger, Vice President-Information Technology

Who are some of Arvinas' key competitors?

Some companies that are related to Arvinas include BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Elanco Animal Health (ELAN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), CureVac (CVAC), Bausch Health Companies (BHC), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Legend Biotech (LEGN), Jazz Pharmaceuticals (JAZZ) and Biohaven Pharmaceutical (BHVN).
View all of ARVN's competitors.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.20%), Bellevue Group AG (4.24%), New Leaf Venture Partners L.L.C. (2.47%), Canaan Partners IX LLC (1.48%), Geode Capital Management LLC (1.44%) and Morgan Stanley (1.41%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends for Arvinas.

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, New Leaf Venture Partners L.L.C., Deutsche Bank AG, Point72 Asset Management L.P., Renaissance Technologies LLC, Millennium Management LLC, Eagle Asset Management Inc., and Rock Springs Capital Management LP. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or view top insider-selling stocks.

Which major investors are buying Arvinas stock?

ARVN stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Voya Investment Management LLC, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., Candriam Luxembourg S.C.A., Geode Capital Management LLC, and Wasatch Advisors Inc.. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or or view top insider-buying stocks.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $75.61.

How much money does Arvinas make?

Arvinas has a market capitalization of $4.00 billion and generates $21.80 million in revenue each year. The company earns $-119.33 million in net income (profit) each year or ($3.80) on an earnings per share basis.

How many employees does Arvinas have?

Arvinas employs 179 workers across the globe.

What is Arvinas' official website?

The official website for Arvinas is www.arvinas.com.

Where are Arvinas' headquarters?

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected].